As many have suggested, I suspect BP is behind the
Post# of 144902
![Avatar](/images/ProfileImages/333117435_64423_dr-zaius2.jpg)
The fact that CytoDyn showed that Leronlimab works in a population where others have failed, like Gilead for instance, should be a huge statement on the potential of this drug, and not just for Covid.
Competitors are worried about leronlimab working in mild to moderate especially if it stops progression into a severe phase, since that is where their products are positioned to target.
And they are likely sweating bullets at the upcoming data in severe covid 19 population!!
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)